Custom-synthesis specialty chemicals & CDMO maker for agrochem, pharma, personal care clients.
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 50 | 100 | 100 | 107 | 110 | 110 | 114 | 114 |
| Reserves | 515 | 1.5k | 1.6k | 2.3k | 2.6k | 2.7k | 3.1k | 3.1k |
| Borrowings | 846 | 423 | 836 | 822 | 1.1k | 1.3k | 1.2k | 1.6k |
| Other Liabilities | 252 | 300 | 325 | 388 | 547 | 752 | 1.2k | 1.1k |
| Total Liabilities | 1.7k | 2.3k | 2.9k | 3.6k | 4.4k | 4.9k | 5.7k | 5.9k |
| AssetsFixed Assets | 978 | 1.1k | 1.2k | 1.2k | 1.3k | 1.8k | 2.4k | 2.5k |
| CWIP | 101 | 42 | 43 | 113 | 579 | 206 | 58 | 68 |
| Investments | 0 | 0 | 148 | 158 | 159 | 159 | 9 | 0 |
| Other Assets | 583 | 1.1k | 1.5k | 2.1k | 2.3k | 2.7k | 3.2k | 3.3k |
| Total Assets | 1.7k | 2.3k | 2.9k | 3.6k | 4.4k | 4.9k | 5.7k | 5.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 42 | 95 | 1 | -171 | 244 | 22 | -65 | 274 |
| Cash from Investing | -261 | -178 | -192 | -412 | -478 | -362 | -286 | -656 |
| Cash from Financing | 209 | 102 | 416 | 384 | 376 | 398 | 192 | 356 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -216 | -85 | -144 | -318 | 37 | -602 | -372 | -169 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (92.8×) and current (89.5×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -3.9% growth and a 89× exit, ₹1277 only delivers your return if you pay ₹419. The price is currently baking in 18% growth.
EPS grows -3.9%/yr for 5 years, then fades to 6% over 2, exits at 89×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -3.9% | 13.71 |
| FY28 | -3.9% | 13.18 |
| FY29 | -3.9% | 12.66 |
| FY30 | -3.9% | 12.17 |
| FY31 | -3.9% | 11.70 |
| FY32 | 1.1% ·fade | 11.82 |
| FY33 | 6.0% ·fade | 12.53 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.